Johnson & Johnson Family of Companies
NEWS
There was a handful of positive clinical trial news reported today. Here’s a look.
The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
J&J did not disclose much information about the unexplained illness, stating, “We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
JOBS
IN THE PRESS